STOCK TITAN

C4 Therapeutics Inc - CCCC STOCK NEWS

Welcome to our dedicated news page for C4 Therapeutics (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect C4 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of C4 Therapeutics's position in the market.

Rhea-AI Summary
C4 Therapeutics, Inc. (CCCC) announces promising preclinical data for CFT1946 and CFT8634 at AACR Annual Meeting 2024. CFT1946 shows superior activity in BRAF V600X melanoma, CRC, NSCLC, and brain metastasis models. CFT8634, a BRD9 BiDAC™ degrader, exhibits activity in multiple myeloma cell line models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
conferences clinical trial
-
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) announces a collaboration with Merck KGaA, Darmstadt, Germany, to discover two targeted protein degraders against critical oncogenic proteins. C4T will receive a $16 million upfront payment and is eligible for up to $740 million in milestone payments, along with royalties. The collaboration aims to advance an exciting program from C4T's internal oncology pipeline, potentially transforming cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Summary
C4 Therapeutics, Inc. reports positive clinical data for CFT7455 in treating relapsed/refractory multiple myeloma and non-Hodgkin’s lymphomas. Encouraging PK and PD data for CFT1946 targeting solid tumors. Financially, revenue decreased in 2023 but the company remains well-capitalized with cash runway expected into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.38%
Tags
earnings
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) announced its 2024 priorities, including multiple clinical updates, a 30% workforce reduction, and a cash runway into 2027. The company also reported unaudited cash, cash equivalents, and marketable securities totaling approximately $330 million as of January 5, 2024. C4T has received additional capital of approximately $107 million and will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
none
-
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) announced the closing of a $25 million stock purchase agreement with Betta Pharmaceuticals Co. Ltd (300558.SZ), a leading pharmaceutical company in China. The investment was completed at $4.49 per share, representing a 25% premium over the 60-trading-day volume weighted average.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, to discuss advancements in targeted protein degradation science and the development of new small-molecule medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.69%
Tags
conferences
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) presents promising clinical data from Phase 1 trial of CFT7455 for multiple myeloma and non-Hodgkin’s lymphomas
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
135.47%
Tags
clinical trial
-
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) has entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs) for cancer treatment. C4T will receive a $10 million upfront payment and is eligible for milestone payments totaling approximately $600 million, as well as tiered royalties on future sales. Merck has the option to extend the collaboration to include three additional targets, potentially resulting in up to approximately $2.5 billion in potential payments across the entire collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
98.31%
Tags
none
-
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) to present new Phase 1 dose escalation data for relapsed refractory multiple myeloma from the ongoing Phase 1/2 clinical trial of CFT7455, a MonoDAC™ degrader of IKZF1/3, for the potential treatment of relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin’s lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
conferences clinical trial
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) appoints Owen Hughes, an accomplished life sciences executive, to its board of directors. Hughes brings nearly three decades of experience in investing, operations, and corporate governance. He is expected to leverage his expertise to strategically advance the company's portfolio of novel degrader medicines, potentially transforming disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
management
C4 Therapeutics Inc

Nasdaq:CCCC

CCCC Rankings

CCCC Stock Data

560.47M
52.51M
14.22%
68.09%
7.71%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Watertown

About CCCC

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.